EFPIA Report Highlights 6 Core Principles to Govern Transparency in Evidence Under Novel Pricing Agreements

Date: May 4, 2021 | Country: BELGIUMNETHERLANDSPORTUGAL | Region: EU27EUROPE | 
Type: Policy | Keywords: #access #affordability #availability #data #datacollection #efpia 
#innovativepaymentmodel #novelpaymentmodel #transparency

PRICENTRIC BRIEF:

  • To contribute to mitigating any issues related to the availability, accessibility, and affordability of medicines, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has published “Addressing Healthcare Challenges: Principles on the Transparency of Evidence from Novel Pricing and Payment Models,” a report identifying core principles to govern the transparency of evidence from novel payment schemes
  • Evidence disclosure should occur (1) when agreeing to a novel pricing and payment model and (2) after the conclusion of the data collection and its analysis
  • While the merits of disclosure will “vary from agreement to agreement and from country to country,” EFPIA wants the following six principles to be considered when it comes to any disclosure or transparency: rationale, mutual agreement, data quality, context of data collection, data interpretation and use, and patient confidentiality 

THE DETAILS

BRUSSELS, Belgium – The number of clinical trials in Europe is increasing, but for the European Federation of Pharmaceutical Industries and Associations (EFPIA), innovation only matters if its reaches patients in a timely manner—stakeholders need to collaborate to address issues related to availability, accessibility, and affordability, which was the recent focus of a conference spearheaded by the Portuguese Presidency of the European Union (EU).

To contribute to mitigating any issues in these three areas, EFPIA has published “Addressing Healthcare Challenges: Principles on the Transparency of Evidence from Novel Pricing and Payment Models,” a report identifying core principles to govern the transparency of evidence from novel payment schemes.

In a press release, EFPIA stated: “The co-creation, adoption and transparency of novel pricing and payments models is just one part of EFPIA and its members’ wider pledge to help address delays and barriers to patients getting access to new treatments. By taking a more holistic and inclusive approach, agreeing on access barriers and co-creating new, flexible and collaborative solutions to ensure faster and more equitable access to medicines across Europe, together in an EU High Level Forum, we will transform the way we think, manage and resource healthcare to the benefit of patients.”

EFPIA is backing greater transparency, but only “in an appropriate manner,” and if it’s “mutually acceptable to payers,” as well as health technology assessment (HTA) bodies.

Evidence disclosure should occur (1) when agreeing to a novel pricing and payment model and (2) after the conclusion of the data collection and its analysis. While the merits of disclosure will “vary from agreement to agreement and from country to country,” EFPIA wants the following six principles to be considered when it comes to any disclosure or transparency: rationale, mutual agreement, data quality, context of data collection, data interpretation and use, and patient confidentiality.

All in all, “Payers, policy makers and the industry should collaborate to improve the transparency of novel pricing and payment models and ensure that the resulting evidence benefits patients and healthcare systems,” said EFPIA.

Learn more about Pricentric ONE and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.